Grisnilimab

Grisnilimab (WT1), a IgG2a monoclonal antibody anti-CD7, is a tumor suppressor involved in the etiology of Wilms' tumor. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA[1].

Product Specifications

CAS Number

[2367001-70-3]

Product Name Alternative

WT1

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/grisnilimab.html

Purity

99.43

Solubility

10 mM in DMSO

Smiles

[Grisnilimab]

Molecular Weight

(146.39 kDa)

References & Citations

[1]Scharnhorst V, et al. WT1 proteins: functions in growth and differentiation. Gene. 2001 Aug 8;273 (2) :141-61.|[2]Hertler AA, et al. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother. 1989;28 (1) :59-66.